Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

KeraVision

This article was originally published in The Gray Sheet

Executive Summary

Ad campaign for Intacs intrastromal corneal ring segments to treat mild nearsightedness commences the week of May 15 in 20 U.S. cities. The device gained FDA approval last year (1"The Gray Sheet" April 19, 1999, p. 12). The company plans to spend up to $5 mil. for radio, print and direct mail ads in the consumer campaign, the company says in a May 18 release

You may also be interested in...



KeraVision Eying Over 200 U.S. Centers With 3 Intacs Distribution Deals

KeraVision began its roll-out of Intacs intrastromal ring segments less than a week following FDA approval April 9, backed by distribution agreements with three major U.S. outlets serving over 200 eye care centers.

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Health And Wellness Weekly Trademarks Review: 16 April

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT013408

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel